ATHE vs. NNVC, CARA, NRXP, PMN, NLTX, VYNE, MRKR, ACST, UNCY, and BOLT
Should you be buying Alterity Therapeutics stock or one of its competitors? The main competitors of Alterity Therapeutics include NanoViricides (NNVC), Cara Therapeutics (CARA), NRx Pharmaceuticals (NRXP), ProMIS Neurosciences (PMN), Neoleukin Therapeutics (NLTX), VYNE Therapeutics (VYNE), Marker Therapeutics (MRKR), Acasti Pharma (ACST), Unicycive Therapeutics (UNCY), and Bolt Biotherapeutics (BOLT). These companies are all part of the "pharmaceutical preparations" industry.
NanoViricides (NYSE:NNVC) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, community ranking, dividends and valuation.
NanoViricides has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500. Comparatively, Alterity Therapeutics has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500.
Alterity Therapeutics has a consensus price target of $4.00, suggesting a potential upside of 110.80%. Given NanoViricides' higher possible upside, analysts clearly believe Alterity Therapeutics is more favorable than NanoViricides.
NanoViricides has higher earnings, but lower revenue than Alterity Therapeutics.
10.3% of NanoViricides shares are held by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are held by institutional investors. 4.6% of NanoViricides shares are held by company insiders. Comparatively, 38.8% of Alterity Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Alterity Therapeutics received 3 more outperform votes than NanoViricides when rated by MarketBeat users. Likewise, 60.00% of users gave Alterity Therapeutics an outperform vote while only 0.00% of users gave NanoViricides an outperform vote.
In the previous week, NanoViricides had 1 more articles in the media than Alterity Therapeutics. MarketBeat recorded 1 mentions for NanoViricides and 0 mentions for Alterity Therapeutics. Alterity Therapeutics' average media sentiment score of 0.50 beat NanoViricides' score of 0.00 indicating that NanoViricides is being referred to more favorably in the media.
NanoViricides' return on equity of 0.00% beat Alterity Therapeutics' return on equity.
Summary
Alterity Therapeutics beats NanoViricides on 8 of the 13 factors compared between the two stocks.
Get Alterity Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATHE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ATHE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alterity Therapeutics Competitors List
Related Companies and Tools
